Considerations on clinical trials of leprosy treatment: need of novel drug combinations
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2013 |
| Outros Autores: | , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/11778 |
Resumo: | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil. |
| id |
CRUZ_38f31e94b89bc6485b13e01ea7560174 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/11778 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Illarramendi Rojas, XimenaOliveira, Maria Leide Wand del Rey deSales, Ana MariaNery, José Augusto da CostaSarno, Euzenir Nunes2015-09-21T17:25:45Z2015-09-21T17:25:45Z2013ILLARRAMENDI ROJAS, Ximena et al. Considerations on clinical trials of leprosy treatment: need of novel drug combinations. Clin. Invest., v.3, n.7, p.617-635, 2013.https://www.arca.fiocruz.br/handle/icict/1177810.4155/CLI.13.52engFuture Science GroupResistênciaClinical trialDrug combinationLeprosyMultidrug therapyRelapseResistanceSurrogate end pointTreatmentHanseníaseEnsaio ClínicoMúltiplos MedicamentosRecidivaConsiderations on clinical trials of leprosy treatment: need of novel drug combinationsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.Universidade Federal do Rio de Janeiro. Departamento de Dermatologia. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.Considering that after 30 years of using multidrug therapy (MDT), leprosy eradication has still not been achieved, leprosy treatment must remain on the drug discovery agenda. Due to the complexities inherent in leprosy disease and the many methodological issues involved in clinical trials, the task of translating the bench findings into clinical practice has been arduous. While the effectiveness of reducing the currently recommended MDT remains controversial, a number of highly bactericidal antibiotics and immune-modulatory drugs have emerged as prospective candidates to improve patient adherence and quality of life, reduce adverse effects and prevent resistance. To replace the standard WHO-MDT, the new combination must be the shortest, simplest and, consequently, most affordable treatment possible.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txttext/plain1914https://www.arca.fiocruz.br/bitstream/icict/11778/1/license.txt7d48279ffeed55da8dfe2f8e81f3b81fMD51ORIGINALeuzenir_sarno_etal_IOC_2013.pdfapplication/pdf1786898https://www.arca.fiocruz.br/bitstream/icict/11778/2/euzenir_sarno_etal_IOC_2013.pdff850f16e40809a7ef8ae00456316c820MD52TEXTeuzenir_sarno_etal_IOC_2013.pdf.txteuzenir_sarno_etal_IOC_2013.pdf.txtExtracted texttext/plain103904https://www.arca.fiocruz.br/bitstream/icict/11778/3/euzenir_sarno_etal_IOC_2013.pdf.txt4c9033048598cbac9cb0c57a0dd3bdfbMD53icict/117782022-06-24 12:18:58.771oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-06-24T15:18:58Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Considerations on clinical trials of leprosy treatment: need of novel drug combinations |
| title |
Considerations on clinical trials of leprosy treatment: need of novel drug combinations |
| spellingShingle |
Considerations on clinical trials of leprosy treatment: need of novel drug combinations Illarramendi Rojas, Ximena Resistência Clinical trial Drug combination Leprosy Multidrug therapy Relapse Resistance Surrogate end point Treatment Hanseníase Ensaio Clínico Múltiplos Medicamentos Recidiva |
| title_short |
Considerations on clinical trials of leprosy treatment: need of novel drug combinations |
| title_full |
Considerations on clinical trials of leprosy treatment: need of novel drug combinations |
| title_fullStr |
Considerations on clinical trials of leprosy treatment: need of novel drug combinations |
| title_full_unstemmed |
Considerations on clinical trials of leprosy treatment: need of novel drug combinations |
| title_sort |
Considerations on clinical trials of leprosy treatment: need of novel drug combinations |
| author |
Illarramendi Rojas, Ximena |
| author_facet |
Illarramendi Rojas, Ximena Oliveira, Maria Leide Wand del Rey de Sales, Ana Maria Nery, José Augusto da Costa Sarno, Euzenir Nunes |
| author_role |
author |
| author2 |
Oliveira, Maria Leide Wand del Rey de Sales, Ana Maria Nery, José Augusto da Costa Sarno, Euzenir Nunes |
| author2_role |
author author author author |
| dc.contributor.author.fl_str_mv |
Illarramendi Rojas, Ximena Oliveira, Maria Leide Wand del Rey de Sales, Ana Maria Nery, José Augusto da Costa Sarno, Euzenir Nunes |
| dc.subject.other.pt_BR.fl_str_mv |
Resistência |
| topic |
Resistência Clinical trial Drug combination Leprosy Multidrug therapy Relapse Resistance Surrogate end point Treatment Hanseníase Ensaio Clínico Múltiplos Medicamentos Recidiva |
| dc.subject.en.pt_BR.fl_str_mv |
Clinical trial Drug combination Leprosy Multidrug therapy Relapse Resistance Surrogate end point Treatment |
| dc.subject.decs.pt_BR.fl_str_mv |
Hanseníase Ensaio Clínico Múltiplos Medicamentos Recidiva |
| description |
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil. |
| publishDate |
2013 |
| dc.date.issued.fl_str_mv |
2013 |
| dc.date.accessioned.fl_str_mv |
2015-09-21T17:25:45Z |
| dc.date.available.fl_str_mv |
2015-09-21T17:25:45Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
ILLARRAMENDI ROJAS, Ximena et al. Considerations on clinical trials of leprosy treatment: need of novel drug combinations. Clin. Invest., v.3, n.7, p.617-635, 2013. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/11778 |
| dc.identifier.doi.pt_BR.fl_str_mv |
10.4155/CLI.13.52 |
| identifier_str_mv |
ILLARRAMENDI ROJAS, Ximena et al. Considerations on clinical trials of leprosy treatment: need of novel drug combinations. Clin. Invest., v.3, n.7, p.617-635, 2013. 10.4155/CLI.13.52 |
| url |
https://www.arca.fiocruz.br/handle/icict/11778 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Future Science Group |
| publisher.none.fl_str_mv |
Future Science Group |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/11778/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/11778/2/euzenir_sarno_etal_IOC_2013.pdf https://www.arca.fiocruz.br/bitstream/icict/11778/3/euzenir_sarno_etal_IOC_2013.pdf.txt |
| bitstream.checksum.fl_str_mv |
7d48279ffeed55da8dfe2f8e81f3b81f f850f16e40809a7ef8ae00456316c820 4c9033048598cbac9cb0c57a0dd3bdfb |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813009248943079424 |